28.3 C
New York
Friday, July 11, 2025

Tag: vectors

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Saint Herblain (France), July, 11 2025Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).

Zilliz Named “Highest Performer” and “Easiest to Use” in G2’s Summer 2025 Grid® Report for Vector Databases

Dual recognition from G2 validates Zilliz's breakthrough approach to delivering enterprise-grade performance without operational complexity. SAN FRANCISCO, July 11, 2025 /PRNewswire/ -- Zilliz, the company behind...

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation...

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential approval

Viral Vectors & Plasmid DNA Manufacturing Market Report 2025-2035 | Gene Therapy Boom Fuels Demand, Regulatory Hurdles Challenge Growth in Gene Therapy Manufacturing

The Viral Vectors and Plasmid DNA Manufacturing Market forecast indicates a surge past $6 billion by 2025, driven by gene therapy advancements. The report highlights market dynamics, growth prospects, and regulatory challenges impacting this sector. Discover innovative opportunities and key players in this evolving landscape.
The Viral Vectors and Plasmid DNA Manufacturing Market forecast indicates a surge past $6 billion by 2025, driven by gene therapy advancements. The report highlights market dynamics, growth prospects, and regulatory challenges impacting this sector. Discover innovative opportunities and key players in this evolving landscape.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsVectors